Lucy Foley appointed to BioPhorum Strategic Advisory Board

eXmoor Pharma’s CEO, Lucy Foley, has been appointed to BioPhorum’s newly established Strategic Advisory Board, bringing senior executive insight from the cell and gene therapy CDMO sector to the organisation’s highest advisory forum.

Announced in February 2026, BioPhorum’s inaugural Strategic Advisory Board brings together 14 senior leaders from across pharma, biotech, manufacturing and supply chain organisations. The Board has been formed to provide high-level guidance and C-suite perspective, helping ensure BioPhorum’s work continues to address the most pressing challenges facing the pharmaceutical industry.

The Board will act as a forum for strategic dialogue across areas including global regulation, emerging technologies and supply chain resilience. Members include executives from Pfizer, GSK, Eli Lilly, Amgen, Sanofi, Merck, SK Pharmteco, Fujifilm BioTechnologies, Sartorius, UCB, Cytiva and eXmoor Pharma.

Commenting on her appointment, Lucy Foley said:

“BioPhorum plays an important role in bringing industry leaders together around shared, practical challenges. As manufacturing technologies, regulatory expectations and supply models continue to evolve, that kind of executive-led collaboration is increasingly valuable. I’m pleased to be joining the Strategic Advisory Board and look forward to contributing to discussions that help shape how our industry responds to these changes.”

Lucy Foley

CEO, eXmoor Pharma

Lucy brings extensive leadership experience across biopharma manufacturing, consultancy and technology translation, informed by roles in industry and academia. As CEO of eXmoor Pharma, she leads an integrated CDMO model that combines CMC strategy, process development and GMP manufacturing to support developers from early-phase planning through to clinical delivery.

The Strategic Advisory Board is chaired by Uwe Buecheler, with BioPhorum CEO Deborah Kobewka noting that the Board represents a key milestone in strengthening executive-level collaboration across the industry.

Further details on the Strategic Advisory Board and its members are available via BioPhorum’s announcement here.